**SUPPLEMENTARY MATERIAL**

**Temporal trends and transmission dynamics of pre-treatment HIV-1 drug resistance within and between risk groups in Kenya, 1986-2020.**

George M. Nduva1,2\*, Frederick Otieno3, Joshua Kimani4,5, Yiakon Sein2, Dawit A. Arimide1, Lyle R. McKinnon4,5,6, Francois Cholette5,7, Morris K. Lawrence8, Maxwell Majiwa9, Moses Masika10, Gaudensia Mutua10, Omu Anzala11, Susan M. Graham2,12, Larry Gelmon4,5, Matt A. Price12,13, Adrian D. Smith15, Robert C. Bailey3,13, Patrik Medstrand1, Eduard J. Sanders2,15#, Joakim Esbjörnsson1,15#, and Amin S. Hassan1,2#\*.

#Equal contribution as senior authors

1Lund University, Lund, Sweden, 2KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya, 3Nyanza Reproductive Health Society, Kisumu, Kenya, 4University of Nairobi, Nairobi, Kenya, 5University of Manitoba, Winnipeg, Canada, 6Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa, 7National Microbiology Laboratory at the JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Canada, 8Pwani University, Kilifi, Kenya, 9KEMRI/Center for Global Health Research, Kisumu, Kenya, 10KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya, 11University of Washington, Seattle, USA, 12IAVI, New York, USA, 13University of California, San Francisco, USA, 14University of Illinois at Chicago, USA, 15University of Oxford, Oxford, United Kingdom.

**Files in this Data Supplement:**

Table S1. Frequency of drug class-specific pre-treatment HIV drug resistance mutations in different risk groups in Kenya (n=3567, 1986-2020).

Table S2. Frequency of drug class-specific pre-treatment HIVDR mutations by drug class and risk group among ART-naïve individuals in Kenya (n=3567, 1986-2020).

Table S3. Temporal trends in HIV-1 drug resistance among ART naïve individuals with different risk groups in Kenya (1986-2020).

# Table S1. Frequency of drug class-specific pre-treatment HIV drug resistance mutations in different risk groups in Kenya, including the frequencies, (proportions and 95% confidence intervals [95% CI]) (n=3567, 1986-2020).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Drug class** | **Overall** | **HET** | **MSM** | **FSW** | **PWID** | **Children** |
| Any HIVDR  | 550/3567(15.4 [14.2-16.6]) | 411/2947(13.9 [12.7-15.2]) | 68/341(20.0 [15.8-24.6]) | 22/146(15.1 [9.7-21.9]) | 18/58(31.0 [19.5-44.5]) | 31/75(41.3 [30.1-53.3]) |
| NNRTI | 453/3567(12.7 [11.6-13.8]) | 345/2947(11.7 [10.6-12.9]) | 62/341(18.2 [14.2-22.7]) | 16/146(11.0 [6.4-17.2]) | 1/58(1.7 [0-9.2]) | 29/75(38.7 [27.6-50.6]) |
| NRTI | 232/3567(6.5 [5.7-7.4]) | 172/2947(5.8 [5.0-6.7]) | 17/341(5.0 [2.9-7.9]) | 10/146(6.8 [0.3-12.3]) | 18/58(31.0 [19.5-44.5]) | 15/75(20.0 [11.6-30.8]) |
| PI | 23/2491(0.9 [0.6-1.4]) | 19/2001(0.9 [0.6-1.5]) | 3/341(0.9 [0.1-2.5]) | 1/146(0.7 [0-3.8]) | (N/A) | 0/3(0.0 [0-70.8]) |
| INSTI | 0/106(0.0 [0.0-3.4\*]) | 0/69(0.0 [0.0-0.5\*]) | 0/21(0.0 [0.0-16.1\*]) | 0/16(0.0 [0.0-20.6\*]) | (N/A) | (N/A) |

*Abbreviations: ART, antiretroviral therapy; HET, presumed heterosexual i.e., men and women not reporting sex work or male same-sex behaviour; MSM, men who have sex with men; PWID, people who inject drugs; FSW, female sex worker; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; INSTI, integrase strand transfer inhibitors. \*One-sided, 97.5% confidence interval.*

# Table S2. Frequency and proportion of drug class-specific pre-treatment HIVDR mutations among sequences from treatment naïve with any pre-treatment HIVDR mutation by drug class and risk group among ART-naïve individuals in Kenya (n=3567, 1986-2020).

|  |  |  |
| --- | --- | --- |
| **Drug class** | **HIVDR mutation** | **Number and proportion**  |
| NNRTI | K103NS | 210 (5.9%) |
| G190ASE | 98 (2.7%) |
| Y181CIV | 65 (1.8%) |
| V179F | 55 (1.5%) |
| V106MA | 45 (1.3%) |
| Y188LHC | 17 (0.5%) |
| K101EP | 16 (0.4%) |
| L100I | 13 (0.4%) |
| M230L | 8 (0.2%) |
| P225H | 5 (0.1%) |
| NRTI | M184VI | 130 (3.6%) |
| T215revs | 56 (1.6%) |
| K70RE | 36 (1.0%) |
| D67NGE | 30 (0.8%) |
| K219QENR | 24 (0.7%) |
| M41L | 20 (0.6%) |
| K65R | 18 (0.5%) |
| V75MTAS | 10 (0.3%) |
| L74VI | 9 (0.3%) |
| L210W | 5 (0.1%) |
| Y115F | 3 (0.1%) |
| T69DIns | 3 (0.1%) |
| F116Y | 2 (0.1%) |
| Q151M | 2 (0.1%) |
| F77L | 1 (0.0%) |
| PI | M46IL | 12 (0.5%) |
| L90M | 3 (0.1%) |
| I54VL | 2 (0.1%) |
| N88DS | 2 (0.1%) |
| D30N | 2 (0.1%) |
| V82A | 1 (0.0%) |
| I47VA | 1 (0.0%) |
| V32I | 1 (0.0%) |
| G48E | 1 (0.0%) |
| INSTI | None | None |

*Abbreviations: ART, anti-retroviral therapy; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; INSTI, integrase strand transfer inhibitors.*

# Table S3. Temporal trends in HIV-1 drug resistance among ART naïve individuals with different risk groups, including the frequencies, (proportions and 95% confidence intervals [95% CI]) in Kenya (1986-2020).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Risk group** | **Years** | **Any HIVDR**  | **NNRTI** | **NRTI** | **PI** | **INSTI** |
| Overall     | Before 2005 | 31/451(6.9 [4.7-9.6]) | 17/451(3.8 [2.2-6]) | 19/451(4.2 [2.6-6.5]) | 0/391(0.0 [0.0-0.9\*]) | 0/60(0.0 [0.0-6.0\*]) |
| 2006-2010 | 268/1997(13.4 [12-15]) | 211/1997(10.6 [9.3-12]) | 115/1997(5.8 [4.8-6.9]) | 17/1611(1.1 [0.6-1.6]) | 0/42(0.0 [0.0-8.4\*]) |
| 2011-2015 | 194/883(22.0 [19.3-24.8]) | 171/883(19.4 [16.8-22.1]) | 79/883(8.9 [7.1-11]) | 3/253(1.1 [0.2-3.4]) | 0/4(0.0 [0.0-60.2\*]) |
| 2016-2020 | 57/236(24.2 [18.8-30.1]) | 54/236(22.9 [17.7-28.8]) | 19/236(8.1 [4.9-12.3]) | 3/236(1.3 [0.3-3.7]) | (N/A) |
| HET    | Before 2005 | 28/427(6.6 [4.4-9.3]) | 16/427(3.7 [2.2-6]) | 17/427(4.0 [2.3-6.3]) | 0/368(0.0 [0.0-1.0]) | 0/52(0.0 [0.0-6.8\*]) |
| 2006-2010 | 229/1736(13.2 [11.6-14.9]) | 194/1736(11.2 [9.7-12.8]) | 93/1736(5.4 [4.3-6.5]) | 16/1408(1.1 [0.7-1.8]) | 0/17(0.0 [0.0-19.5\*]) |
| 2011-2015 | 152/753(20.2 [17.4-23.2]) | 133/753(17.7 [15-20.6]) | 61/753(8.1 [6.3-10.3]) | 2/194(1.0 [0.1-3.7]) | (N/A) |
| 2016-2020 | 2/31(6.5 [0.8-21.4]) | 2/31(6.5 [0.8-21.4]) | 1/31(3.2 [0.1-16.7]) | 1/31(3.2 [0.1-16.7]) | (N/A) |
| MSM    | Before 2005 | (N/A) | (N/A) | (N/A) | (N/A) | (N/A) |
| 2006-2010 | 15/113(13.3 [7.6-20.9]) | 13/113(11.5 [6.3-18.9]) | 2/113(1.8 [0.2-6.2]) | 0/113(0.0 [0.0-3.2\*]) | (N/A) |
| 2011-2015 | 8/49(16.3 [7.3-29.7]) | 7/49(14.3 [5.9-27.2]) | 2/49(4.1 [0.5-14]) | 1/49(2 [0.1-10.9]) | 0/13(0.0 [0.0-24.7\*]) |
| 2016-2020 | 45/179(25.1 [19-32.2]) | 42/179(23.5 [17.5-30.4]) | 13/179(7.3 [3.9-12.1]) | 2/179(1.1 [0.1-4.0]) | 0/1(0.0 [0.0-97.5\*]) |
| PWID    | Before 2005 | (N/A) | (N/A) | (N/A) | (N/A) | (N/A) |
| 2006-2010 | 18/58(31.0 [19.5-44.5]) | 1/58(1.7 [0.0-9.2]) | 18/58(31 [19.5-44.5]) | (N/A) | 0/58(0.0 [0.0-6.2\*]) |
| 2011-2015 | (N/A) | (N/A) | (N/A) | (N/A) | (N/A) |
| 2016-2020 | (N/A) | (N/A) | (N/A) | (N/A) | (N/A) |
| FSW    | Before 2005 | 3/20(15.0 [3.2-37.9]) | 1/20(5.0 [0.1-24.9]) | 2/20(10.0 [1.2-31.7]) | 3/20(15.0 [3.2-37.9]) | 0/8(0.0 [0.0-36.9]) |
| 2006-2010 | 6/90(6.7 [2.5-13.9]) | 3/90(3.3 [0.7-9.4]) | 2/90(2.2 [0.3-7.8]) | 1/90(1.1 [0.0-6.0]) | 0/8(0.0 [0.0-36.9]) |
| 2011-2015 | 3/10(30.0 [6.7-65.2]) | 2/10(20 [2.5-55.6]) | 1/10(10.0 [0.3-44.5]) | 0/10(0.0 [0.0-30.8\*]) | (N/A) |
| 2016-2020 | 10/26(38.5 [20.2-59.4]) | 10/26(38.5 [20.2-59.4]) | 5/2619.2 (6.6-39.4) | 0/26(0.0 [0.0-13.2\*]) | (N/A) |
| Children    | Before 2005 | 0/4(0.0 [0.0-60.2\*]) | 0/4(0.0 [0.0-60.2\*]) | 0/4(0.0 [0.0-60.2\*]) | 0/3(0.0 [0.0-70.6\*]) | (N/A) |
| 2006-2010 | (N/A) | (N/A) | (N/A) | (N/A) | (N/A) |
| 2011-2015 | 31/71(43.6 [31.9-56.0]) | 29/71(40.8 [29.3-53.2]) | 15/71(21.1 [12.3-32.4]) | (N/A) | (N/A) |
| 2016-2020 | (N/A) | (N/A) | (N/A) | (N/A) | (N/A) |

*Abbreviations: MSM, men who have sex with men; PWID, people who inject drugs; FSW, female sex worker; HET, at-risk men and women who did not report sex work or male same-sex behaviour; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; INSTI, integrase strand transfer inhibitors.*

*\* One-sided, 97.5% confidence interval.*